Enabling Early Drug Discovery: Integrated Screening Capabilities and a BRD4/CRBN PROTAC Case Study
Enamine is a global provider of integrated drug discovery solutions supporting early-stage research through access to compound libraries and experimental screening capabilities. Its platform enables efficient progression of discovery projects by integrating assay development, high-throughput screening workflows, and biophysical and cell-based characterization methods.
Targeted protein degradation has emerged as a powerful approach in cancer drug discovery, enabling modulation of previously undruggable targets through induced protein degradation mechanisms.
Using a BRD4/CRBN PROTAC case study, we will present a stepwise screening approach for identifying initial degrader candidates. The workflow includes primary screening, followed by biophysical characterization and cell-based assessment of target engagement and degradation effects. Particular emphasis will be placed on assay selection strategy, data triaging, and progression criteria applied during hit identification.
The example illustrates how complementary experimental readouts are integrated to support evaluation of early PROTAC candidates and guide progression within early-stage discovery programs.
Enamine is a global provider of integrated drug discovery solutions supporting early-stage research through access to compound libraries and experimental screening capabilities. Its platform enables efficient progression of discovery projects by integrating assay development, high-throughput screening workflows, and biophysical and cell-based characterization methods.
Show more
Targeted protein degradation has emerged as a powerful approach in cancer drug discovery, enabling modulation of previously undruggable targets through induced protein degradation mechanisms.
Using a BRD4/CRBN PROTAC case study, we will present a stepwise screening approach for identifying initial degrader candidates. The workflow includes primary screening, followed by biophysical characterization and cell-based assessment of target engagement and degradation effects. Particular emphasis will be placed on assay selection strategy, data triaging, and progression criteria applied during hit identification.
The example illustrates how complementary experimental readouts are integrated to support evaluation of early PROTAC candidates and guide progression within early-stage discovery programs.
Justyna Adamczyk
Justyna Adamczyk is a Lead Scientist and Project Manager at Enamine, a global provider of small molecules and integrated drug discovery services. With over seven years of industry experience, she leads and supports early-stage drug discovery programs, with a focus on the design and execution of high-throughput and targeted screening strategies.
Her expertise spans protein – ligand interaction studies, assay development, and targeted protein degradation, integrating biophysical and cell-based approaches. She brings extensive experience in high-throughput screening (HTS), including the establishment of screening platforms and the delivery of complex screening campaigns across diverse target classes.
Justyna Adamczyk is a Lead Scientist and Project Manager at Enamine, a global provider of small molecules and integrated drug discovery services. With over seven years of industry experience, she leads and supports early-stage drug discovery programs, with a focus on the design and execution of high-throughput and targeted screening strategies.
Show more
Justyna works closely with international partners across the United States, Europe, and Asia, contributing to global discovery programs by aligning scientific strategy with efficient project execution. Her work supports hit identification and validation, enabling decision-making in early drug discovery pipelines.
She holds a Master’s degree in Chemistry and completed doctoral studies in a related field.
Show more
Her expertise spans protein – ligand interaction studies, assay development, and targeted protein degradation, integrating biophysical and cell-based approaches. She brings extensive experience in high-throughput screening (HTS), including the establishment of screening platforms and the delivery of complex screening campaigns across diverse target classes.
Justyna works closely with international partners across the United States, Europe, and Asia, contributing to global discovery programs by aligning scientific strategy with efficient project execution. Her work supports hit identification and validation, enabling decision-making in early drug discovery pipelines.
She holds a Master’s degree in Chemistry and completed doctoral studies in a related field.
Read the Abstracts from Our Invited Speakers
Cancer Biology
- AllergoOncology: Lessons Learned from the Allergy-Glioblastoma Connection
Aurélie Poli, Luxembourg Institute of Health, LUXEMBOURG
- Cytotoxic NK Cells Impede Response to Checkpoint Immunotherapy in Melanoma with an Immune-Excluded Phenotype
Joanna Poźniak, KU Leuven, BELGIUM
- Inducing Immunogenic Tertiary Lymphoid Structures Across Cancer Types With Dendritic Cell Reprogramming
Camille Chatelain, Lund University, SWEDEN
- The Role of ILC2 in Tissue Homeostasis and Neoplasia
Tim Halim, Cancer Research UK Cambridge Institute, UNITED KINGDOM
Cancer Neuroscience
- Latent Neuropathy in Colorectal Cancer: Implications for Cancer Survivorship
Andrew Shepherd, University of Texas MD Anderson Cancer Center, USA
- Remodelling of the Bone Microenvironment During Cancer Infiltration: Insights from Multiplex Imaging and Spatial Transcriptomics
Christina Møller Andreasen, University of Southern Denmark, DENMARK
- Enteric Nervous System-Derived VIP Restrains Differentiation of LGR5+ Stem Cells Towards the Secretory Lineage Impeding Type 2 Immune Programs
Christoph Klose, Charité – Berlin University Medicine, GERMANY
Cancer Therapy
- Targeting the Dark Matter of Cancer with AI-Designed Mini Binder
Tobias Bald, University of Bonn, GERMANY
- Engineering Nanomedicines for Targeted Neuroimmune Modulation
Helena Florindo, University of Lisbon, PORTUGAL
- Potentiating Immunotherapy of Urological Cancers with Oncolytic Viruses
Gabri van der Pluijm, Leiden University Medical Center, THE NETHERLANDS
- Strategic Priorities in Cancer Therapy: Navigating the 2026 Cancer Mission Calls
Industry Contact Point, Łukasiewicz – PORT, POLAND
- Cancer Neuroscience of Brain TumorsKEYNOTE SPEAKER
Frank Winkler, Universitätsklinik Heidelberg, GERMANY
- Spatial Reprogramming of Immune Surveillance in Breast Cancer: From Immune Control to Immune Failure
Sheeba Irshad, King’s College London, UNITED KINGDOM
- The War Against Glioblastoma Needs More Than Standard of Care
Stefaan Van Gool, IOZK Immun-Onkologisches Zentrum Köln, GERMANY
- Uncovering the Spatial Regulation of γδ T Cells: Toward Receptor-Guided Immunotherapy
Jürgen Kuball, University Medical Center Utrecht, THE NETHERLANDS
- CAR‑T Cell Therapy in Lymphomas, Acute Lymphoblastic Leukemia, and Multiple Myeloma
Wojciech Szlasa, DCOPIH, POLAND
- Expanding CAR Targets to Non Protein Antigens
Sébastien Wälchli, Oslo University Hospital, NORWAY
- Advancing BIA-ALCL Research Through a UK – PORT Alliance — From Biobanking to Immune Discovery
Helen Kakkassery, King’s College London, UNITED KINGDOM
PORT for Business — Company Session
- Beyond glioblastoma — WPD Pharmaceuticals
Marek Sipowicz, WPD Pharmaceuticals, POLAND
- The Development of USP7 Inhibitor for Cancer Immunotherapy
Zbigniew Zasłona, Molecule, POLAND
- Leveraging Cancer Biology for Therapeutic Innovation: Clinical and Discovery Advances at Ryvu
Milena Mazan, Ryvu Therapeutics, POLAND
- Transforming Multimodal Complexity into Precision Oncology Insights
Marek Kudła, Ardigen, POLAND
- JJP-1008 as a Novel Checkpoint Inhibitor
Agata Drewniak-Maksymów, JPP Biologics, POLAND
- Synergistic Nanotechnology for Targeted Therapeutics in Oncology
Artur Wnorowski, Biotechna, POLAND
- Development of Biological Drugs for Oncological Indications at Mabion
Jakub Knurek, Mabion, POLAND
- Enabling Early Drug Discovery: Integrated Screening Capabilities and a BRD4/CRBN PROTAC Case Study
Justyna Adamczyk, Enamine, POLAND